Lilly Q1 2026 earnings call: every retatrutide comment in one place

• Lilly reaffirmed prior guidance that the first TRIUMPH topline readout — TRIUMPH-1, in adults with obesity without diabetes — is expected during 2026. The window was not narrowed further.
• No change to enrollment status: all four TRIUMPH pivotal trials remain fully enrolled, as first confirmed in August 2025.
• No new retatrutide efficacy or safety data were disclosed on the call. The program narrative continues on the timeline Lilly has held since the readout schedule was first guided.

Lilly leadership reiterated that the TRIUMPH Phase 3 program remains on schedule, with the first topline readout expected during 2026. The language tracked prior guidance — no acceleration, no delay, and no re-scoping of which trial reads out first.

Executives again framed retatrutide as the successor program to tirzepatide in Lilly's incretin portfolio, pointing to the four fully enrolled TRIUMPH studies as the basis for the planned regulatory submission. Enrollment status was described as unchanged from the company's August 2025 confirmation that TRIUMPH-1 through TRIUMPH-4 had all completed enrollment.

Prepared remarks did not include new manufacturing announcements specific to retatrutide beyond the capacity expansion plans outlined at the company's February 2026 investor day.

Sell-side questions on retatrutide focused on the timing of the first TRIUMPH readout and on how Lilly is sequencing the launch build-out ahead of data. Management held to prior guidance throughout: a 2026 first readout, with no narrower window offered.

No new quantitative detail — on enrollment totals, dose arms, or event accrual — was disclosed during the Q&A.

Prior guidance was reaffirmed, not refined and not withdrawn. The 2026 first-readout window stands, and the sequential readout cadence across TRIUMPH-1 through TRIUMPH-4 — spanning 2026 into 2027 — remains the working assumption. For a program of this size, an uneventful quarter is itself meaningful: fully enrolled trials with unchanged guidance means the readout calendar is now driven by data lock and analysis timelines rather than by recruitment.

Retatrutide remains investigational. No regulator has approved it, and nothing on this call changed that status.

• TRIUMPH-1 topline results — the first and largest Phase 3 readout, expected during 2026. See our reader's guide for how to interpret the headline number when it lands.
• The TRIUMPH-3 cardiovascular readout window, which sell-side coverage has narrowed to late 2026 / early 2027 based on event-rate pacing.
• Lilly's Q2 2026 earnings call — the focal questions will be whether the 2026 window tightens and whether any regulatory-filing timing is disclosed.